Recursion Pharmaceuticals (RXRX) Preferred Stock Liabilities (2020 - 2021)
Recursion Pharmaceuticals (RXRX) reported Preferred Stock Liabilities of $448.3 million for Q1 2021, up 122.92% on a YoY basis from $201.1 million in Q1 2020, and little changed quarter-over-quarter from $448.3 million in Q4 2020.
Recursion Pharmaceuticals (RXRX) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Recursion Pharmaceuticals has reported Preferred Stock Liabilities for 2 years, with the latest figure at $448.3 million in Q1 2021.
- For the quarter ending Q1 2021, Preferred Stock Liabilities rose 122.92% year-over-year to $448.3 million; the trailing twelve-month figure through Mar 2021 stood at $448.3 million (up 122.92% YoY), and the FY2020 full-year result was $448.3 million, up 122.92% from the prior year.
- Preferred Stock Liabilities for Q1 2021 stood at $448.3 million, roughly flat from $448.3 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $448.3 million in Q4 2020, with the low at $201.1 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.71 Bn | 1.05 Bn | -6.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 448.31 Mn |
| Dec 31, 2020 | 448.31 Mn |
| Sep 30, 2020 | 437.92 Mn |
| Jun 30, 2020 | 201.11 Mn |
| Mar 31, 2020 | 201.11 Mn |